Risperidone

Risperdal e altri

Bibliografia - Quali fonti bibliografiche per Risperidone?

1. Assie M.B. et al., Eur. J. Pharmacol., 1993, 237 (2-3), 183.


2. Baptista T. et al., Pharmacopsychiatry, 2002, 35, 205.


3. Chetty M. et al., Br J Clin Pharmacol., 2009, 68(4), 574.


4. Claus A. et al., Acta Psychiat. Scand., 1992, 85, 295.


5. Drugs of Today, 1993, 29, 535.


6. Duff G., CEM/CMO, 2004.


7. Ebert U., Epilepsia, 2002, 43, 2.


8. Etain B. et al., Encephale, 2000, 26(5), 81.


9. FDA, Communication Alert, 6 giugno 2008 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm


10. FDA, luglio 2007, in http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108969.htm


11. Findling R.L. et al., Am J Psychiatry., 2004, 161(4), 677.


12. Fukui H., Murai T., Clinical Neuropharmacology, 2002, 25, 269.


13. Gentile S., Psychopharmacology, 2010, 212(2), 119.


14. Gill S.S. et al., Ann Intern Med., 2007, 146, 775.


15. Gluais P. et al., Eur J Pharmacol., 2002, 444(3), 123.


16. Hong X., Wang X., Am J Psychiatry., 2001, 158(10), 1736.


17. Joo S.W et al., Clin. Psychopharmacol. Neurosci., 2022, 20 (4), 675.


18. Jover F. et al., Clinical Neuropharmacology, 2002, 25, 251.


19. Khanna S. et al., Br J Psychiatry, 2005, 187, 229.


20. Kleinberg D.L. et al., J Clin Psychopharmacol, 1999, 19, 57.


21. Klieser E. et al., J. Clin. Psychiat., 1994.


22. Leysen J.E. et al., Mol. Pharmacol., 1992, 41, 495.


23. Lim D.K., Mahendran R., Singapore Medical Journal, 2002, 43, 530.


24. Locatelli I. et al., Eur J Pharm Sci., 2010, 41, 289.


25. Madhusoodanan S., Brenner R., Journal of Clinical Psychiatry, 1996, 57, 549.


26. Mannens G. et al., Psychopharmacology (Berl)., 1994, 114(4), 566.


27. Marder S.R., Meibach R.C., Amer. J. Psychiatry, 1993.


28. Maxwell R.A. et al., J Geriatr Psychiatry Neurol., 2002, 15(2), 77.


29. McCracken JT et al.,  NEJM 2002, 347, 314.


30. Mula M., Monaco F., Clin. Neuropharmacol., 2002, 25(2), 97.


31. Ono S. et al., Psychopharmacology, 2002, 162(1), 50.


32. Peuskens J., Br J Psychiatry, 1995, 166, 712.


33. Pottegard A. et al., Br. J. Clin. Pharmacol., 2018, 84 (9), 2152.


34. Ravindran A. et al., Clin Pharmacokinet., 2004, 43(11), 733.


35. Reeves Roy R. et al., Ann Pharmacother, 2001, 35, 698.


36. Risperdal, scheda prodotto dicembre 2010 (www.accessdata.fda.gov)


37. Risperdal, scheda prodotto marzo 2007


38. Sabuncuoglu O., J Psychopharmacol., 2007, 21(2), 216.


39. Saller C.F. et al., J. Pharmacol. Exp. Ther., 1990, 253, 1162.


40. Scherk H. et al., Arch Gen Psychiatry, 2007, 64(4), 442.


41. Schneeweiss S. et al., CMAJ., 2007, 176, 627.


42. Schotte A. et al., Brain Res.,1993, 631(2), 191.


43. Snoeck E. et al., Psychopharmacology (Berl)., 1995, 122(3), 223.


44. Sommers D.K. et al., Int Clin Psychopharmacol., 1997, 12(3), 141.


45. Spina E. et al., J Clin Psychopharmacol., 2002, 22(4), 419.


46. Spina E. et al., Ther Drug Monit., 2004, 26(4), 386.


47. Strauss M. et al., Psychiatr Prax., 2010, 37, 199.


48. Sund J.T. et al., J Am Acad Child Adolesc Psychiatry., 2003, 42(1), 1.


49. Taipale H. et al., Lancet Psychiatry, 2021, 8 (10), 883.


50. Thyssen A. et al., Clin Pharmacokinet., 2010, 49(7), 465.


51. Trifirò G. et al., Ann Intern Med 2010, 152, 418.


52. Turgay A. et al., Pediatrics., 2002, 110(3), 34.


53. Volavka J.  et al., J Clin Psychiatry, 2004, 65, 57.


54. Whitten J.R., Ruehter V.L., Ann. Clin. Psychiatry, 1997, 9(3), 181.